FOLH1 and neoplasm: In a preclinical study using C57BL/6 mice implanted with RM1-PGLS tumors expressing PSMA, anti-PD-1 in combination with 225Ac-PSMA-617 demonstrated improved tumor control, extended time to progression, and increased survival compared to monotherapies [117].